Q-omics provides the consensus-scored MRPL30 profile across patient tissues and cancer cell-line models. MRPL30 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MRPL30 is differentially expressed in 16, with the highest sampling consensus in BLCA. Additionally, MRPL30 RNA expression shows 19,260 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and BLCA as cancer lineages where MRPL30 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MRPL30 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MRPL30 survival associations across molecular data types. MRPL30 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MRPL30 RNA expression–survival associations across cancer types. High MRPL30 expression shows unfavorable associations in ACC, LIHC, KIRP and LUAD, but favorable associations in KIRC and READ. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MRPL30 RNA expression.
This table summarizes MRPL30 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for MRPL30. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MRPL30 shows higher tumor expression in BLCA, LUAD, LIHC, COAD, LUSC and HNSC. The BLCA box plot shows higher MRPL30 RNA expression in tumor versus normal tissue (log2 FC = +0.569, t-test p < 0.001).
This table shows molecular features associated with MRPL30 in patient tissues and cancer cell lines. In patient samples, MRPL30 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MRPL30 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and UPPER_AERODIGESTIVE_TRACT.
